Journal: The Journal of Experimental Medicine

Article Title: A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor

doi: 10.1084/jem.20100810

Figure Lengend Snippet: Expression of CD160 in tumor blood vessels but not in the blood vessels of healthy tissues. (A) Representative sections of B16 melanoma at day 16 after their subcutaneous injection (top) and healthy mouse heart (bottom), both stained with either CL1-R2 (CD160) or isolectin B4, an endothelial cell marker. Bar, 50 µm. Images are representative of four independent experiments (five mice/group). (B) Sections of human colon tumor (top) and healthy colon (bottom) stained with CL1-R2 (CD160) or a mAb against CD31, a human endothelial cell marker. Images are representative of two patient biopsies. Control IgG1 did not stain and is not shown. Bar, 50 µm.

Article Snippet: The cross-reactivity of CL1-R2 mAb with CD160 mouse proteins has been demonstrated by different means (Fig. S1): (1) using flow cytometry, we found that CL1-R2 stained mouse SVR endothelial cells as well as the BCL-1 mouse B cell chronic lymphocytic leukemia cell line (Fig. S1 A); (2) using immunoprecipitation and Western blotting, we found that the CNX46-3 anti–mouse CD160 mAb (Cedarlane laboratories) immunoprecipitated protein bands from mouse spleen or BCL-1 cells that were blotted by the CL1-R2 mAb (Fig. S1 B); and (3) five CD160 amino acids were identified by mass spectrometry in the CNX43-6–immunoprecipitated 37-kD band blotted with CL1-R2 mAb with a minimum coverage of 37.5% (Fig. S1 C).

Techniques: Expressing, Injection, Staining, Marker, Control